Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer

Lenvatinib is a small oral molecule able to inhibit three of the extracellular and intracellular molecules involved in the modulation of angiogenesis and lymphangiogenesis: vascular endothelial growth factor receptor 1–3, fibroblast growth factor receptor 1–4, and platelet-derived growth factor rece...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Main Authors: Lorusso, Loredana, Pieruzzi, Letizia, Biagini, Agnese, Sabini, Elena, Valerio, Laura, Giani, Carlotta, Passannanti, Paolo, Pontillo-Contillo, Benedetta, Battaglia, Valentina, Mazzeo, Salvatore, Molinaro, Eleonora, Elisei, Rossella
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2016
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5079697/
https://ncbi.nlm.nih.gov/pubmed/27799794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S84625
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados